Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in hepatitis C.

H W Reesink1, D Bresters, C L van der Poel

  • 1Red Cross Blood Bank Amsterdam, The Netherlands.

Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclophosphamide is not associated with clinically relevant late pulmonary dysfunction in Dutch survivors of childhood cancer - The DCCSS-LATER 2 PULM sub-study.

Respiratory medicine·2025
Same author

[A PhD completed. Long-term effects of childhood cancer therapy on oral health].

Nederlands tijdschrift voor tandheelkunde·2024
Same author

Chronic fatigue in childhood cancer survivors is associated with lifestyle and psychosocial factors; a DCCSS LATER study.

ESMO open·2023
Same author

Health-related quality of life in Dutch adult survivors of childhood cancer: A nation-wide cohort study.

European journal of cancer (Oxford, England : 1990)·2021
Same author

Pregnancy, time to pregnancy and obstetric outcomes among female childhood cancer survivors: results of the DCOG LATER-VEVO study.

Journal of cancer research and clinical oncology·2020
Same author

Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve.

Human reproduction (Oxford, England)·2018
Same journal

Abstract from the 41st Nordic Gastroenterology Congress, 8-11 June 2010, Copenhagen, Denmark.

Scandinavian journal of gastroenterology. Supplement·2010
Same journal

Abstracts from the XL Nordic Meeting of Gastroenterology, June 8-11, 2009, Stavanger, Norway.

Scandinavian journal of gastroenterology. Supplement·2009
Same journal

Abstracts of the 39th Nordic Meeting of Gastroenterology, 30th Nordic Meeting of Digestive Endoscopy, 18th Nordic Meeting of Gastrointestinal Motility, and the Annual Endoscopy/Gastroenterology Nurses'/Assistants' Meeting Post-graduate course, 4-6 June 2008, Helsinki, Finland.

Scandinavian journal of gastroenterology. Supplement·2008
Same journal

Abstracts from the XXXVIII Nordic Meeting of Gastroenterology, XXIX Nordic Meeting of Digestive Endoscopy, XVII Nordic Meeting of Gastrointestinal Motility, 6-9 June 2007, Reykjavik, Iceland.

Scandinavian journal of gastroenterology. Supplement·2007
Same journal

Abstracts of the XXXVII Nordic Meeting of Gastroenterology, 3-5 May 2006, Vasteras, Sweden.

Scandinavian journal of gastroenterology. Supplement·2006
Same journal

Novel approaches in the outpatient care of patients with chronic inflammatory bowel disease.

Scandinavian journal of gastroenterology. Supplement·2006
See all related articles

Hepatitis C virus (HCV) causes chronic infection in 80% of cases, often leading to liver cirrhosis and cancer. Current antiviral therapy offers limited success, with no vaccine available.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis B virus (HBV) and hepatitis A virus were identified, but a significant portion of viral hepatitis cases remained unclassified.
  • Approximately 90% of transfusion-related hepatitis cases were identified as non-A/non-B hepatitis.
  • In 1988, the hepatitis C virus (HCV) was detected, leading to the development of diagnostic assays.

Purpose of the Study:

  • To describe the characteristics of hepatitis C virus (HCV) infection.
  • To outline the transmission routes and clinical outcomes associated with HCV.
  • To review current treatment options and prevention strategies for HCV.

Main Methods:

  • Detection of the non-A, non-B hepatitis agent and naming it hepatitis C virus (HCV).

Related Experiment Videos

  • Development of anti-HCV antibody assays (ELISA) and confirmation tests (immunoblot, PCR).
  • Review of clinical data on HCV infection, transmission, and treatment outcomes.

    • Main Results:

    • HCV infection leads to a chronic carrier state in about 80% of individuals.
    • Nearly all HCV carriers exhibit histologic signs of chronic hepatitis or liver cirrhosis, regardless of liver function tests.
    • HCV infection is associated with hepatocellular carcinoma, similar to HBV.
    • Parenteral routes, including intravenous drug use and blood transfusions, are the primary modes of HCV transmission.
    • Intravenous drug users and hemophilia patients have the highest risk (80-90%) of HCV infection.
    • Sexual and perinatal transmission play minor roles in HCV spread.
    • Alpha-interferon therapy normalizes liver function tests in about 25% of chronic hepatitis C patients, but long-term efficacy regarding viral clearance and cirrhosis prevention remains uncertain.

    Conclusions:

    • Hepatitis C virus (HCV) infection frequently results in chronic disease, liver cirrhosis, and an increased risk of hepatocellular carcinoma.
    • Parenteral transmission is the predominant route for HCV infection, with specific high-risk groups identified.
    • Current antiviral therapies demonstrate limited effectiveness, and no preventative vaccines or immunoglobulins are available for HCV.